Page 3 - ஹார்வர்ட் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஹார்வர்ட் புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஹார்வர்ட் புற்றுநோய் மையம் Today - Breaking & Trending Today

Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior


Published: Jun 09, 2021
By Mark Terry
Kojin Therapeutics
launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
The approach came out of the
laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis. ....

United States , Al Iskandariyah , Harvard University , Dana Farber Cancer Institute , Jurgen Eckhardt , Amir Nashat , Benjamin Cravatt , Stephanie Dougan , Joel Barrish , Steve Davidsen , Nagesh Mahanthappa , Susan Langer , Vasanthi Viswanathan , Nortonb Gilula , Stuart Schreiber , Kay Ahn , Sean Morrison , Scripps Research Institute , Broad Institute , Sarcoma Center At Dana Farber , Harvard Medical School , Ludwig Center At Dana Farber Harvard Cancer , Cathay Health , Children Medical Center Research Institute , Department Of Chemistry , Schreiber Lab ,

Dana-Farber announces expanded joint research agreement with Novartis


This 30-year collaboration is unique in its longevity and open scientific exchange.
Aiming to accelerate the translation of scientific discoveries into improved cancer therapies, Dana-Farber Cancer Institute and Novartis have renewed a longstanding research collaboration and – for the first time – are inviting grant applications from a broad range of Boston academic medical institutions. Under this renewal, more than $11 million will be available annually for research funding through the Dana-Farber/Novartis Drug Discovery and Translational Research Program (DDTRP).
The collaboration, which began in 1992, brings together scientists from Dana-Farber and Novartis to work on drug discovery and development efforts and has supported more than 700 research projects since inception. ....

United States , Harvard School Of Public Health , Dana Farber Cancer Institute , William Hahn , Jay Bradner , James Griffin , Piotr Sicinski , Anne Fassl , Kevin Haigis , Michael Eck , Broad Institute , Novartis Institutes For Biomedical Research , Translational Research Program , Beth Israel Deaconess Medical Center , Drug Administration , Harvard Medical School , Dana Farber Harvard Cancer Center , Novartis Drug Discovery , Chief Operating Officer , Novartis Institutes , Harvard Cancer Center , Boston Children , Massachusetts General Hospital , Harvard School , Public Health , Chief Scientific Officer ,

Dana-Farber Cancer Institute, a Pioneer in Cancer Care and Research, Joins Caris' Precision Oncology Alliance


Share this article
Share this article
IRVING, Texas, Feb. 16, 2021 /PRNewswire/  Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Dana-Farber Cancer Institute (Dana-Farber) has joined Caris Precision Oncology Alliance™ (The Alliance/POA). The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer. At Dana-Farber, it will operate out of the Lank Center for Genitourinary Oncology. ....

New York , United States , Dana Farber Cancer Institute , Chadi Nabhan , Brianj Brille , Lindsey Bailys , Caris Codeai , Dana Farber Brigham , Himisha Beltran , Caris Pharmatech , Time Clinical Trial Solutions , Caris Life Sciences Media Contact , Women Cancer Center , National Cancer Comprehensive Center , Cari Precision Oncology Alliance , Oncology Network , National Comprehensive Cancer Network , Caris Precision Oncology Alliance , Blood Disorders Center , Harvard Medical School , Lank Center , Dana Farber Cancer Institute Media Contact , Precision Oncology Alliance , Dana Farber Harvard Cancer Center , Caris Life Sciences , Boston Children ,

Genomic Test Helps Guide Precision Medicine to Estimate Risk of Prostate Cancer Metastasis, Death


Genomic Test Helps Guide Precision Medicine to Estimate Risk of Prostate Cancer Metastasis, Death
February 11, 2021
San Francisco, CA (UroToday.com)  A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.
Researchers studied prostate cancer samples from 352 participants in the NRG/RTOG 9601 clinical trial, which compared radiation therapy alone with radiation therapy combined with hormone therapy. The investigators found that the Decipher test, which measures the activity of 22 genes among seven known cancer pathways, independently estimated the participants’ risk of metastasis, death from prostate cancer, and overall survival. Researchers say it also guided treatment recommendations for recurrence of prostate cancer after surgery, helping identify patients most li ....

United States , University Of California San Francisco Medical Center , British Columbia , Thomas Jefferson University Hospital , San Diego , City Of , United Kingdom , San Francisco , Los Angeles , Natsar Pharm , Astellas Pharm , Phuoc Tran , Johns Hopkins University , National Cancer Institute , Data Management Center , Centre Hospitalier , University Of Michigan , Johns Hopkins Kimmel Cancer Center , University Of Chicago , York Cancer Center , Sinai Medical Center , College Of Wisconsin , University Of Miami Miller School Medicine , University College , Wellspan Health , Dana Farber Harvard Cancer Center ,